Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019 Aug;10(4):674-87. doi: 10.21037/jgo.2019.03.11
Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Giergiczny M, Dekker T, Hess S, Chintakayala P. Testing the stability of utility parameters in repeated best, repeated best-worst and one-off best-worst studies. Eur J Trans Infra. 2017 Sep 1;17(4):457-76. doi: 10.18757/ejtir.2017.17.4.3209
Novick D, Montgomery W, Aguado J, Peng X, Haro JM. Factors associated with and impact of pain persistence in Asian patients with depression: a 3-month, prospective observational study. Int J Psychiatry Clin Pract. 2017 Mar;21(1):29-35. doi: 10.1080/13651501.2016.1242751
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Novick D, Montgomery W, Aguado J, Peng X, Brugnoli R, Maria Haro J. Impact of anxiety symptoms on outcomes of depression. A study in patients from Asia. Int J Psychiatry Clin Pract. 2013 Nov 5;17(Suppl 2):30-1. doi: 10.3109/13651501.2013.851555
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.